Provided by Tiger Trade Technology Pte. Ltd.

ANTENGENE-B

3.980
+0.0902.31%
Volume:1.96M
Turnover:7.76M
Market Cap:2.69B
PE:-8.98
High:4.120
Open:4.050
Low:3.900
Close:3.890
52wk High:8.160
52wk Low:2.760
Shares:677.00M
HK Float Shares:677.00M
Volume Ratio:1.10
T/O Rate:0.29%
Dividend:- -
Dividend Rate:- -
EPS(LYR):-0.443
ROE:6.39%
ROA:7.21%
PB:2.53
PE(LYR):-8.98
PS:4.08

Loading ...

Antengene Files HKEX Next-day Return Disclosing Share Repurchase at HKD 4.31-4.23

Reuters
·
Jul 13

Antengene Corp Receives Initial $60 Million Upfront Payment from UCB

Reuters
·
Jul 13

Antengene Corp - Receives Initial USD60 Mln Upfront Payment from Ucb

THOMSON REUTERS
·
Jul 13

Antengene Receives USD 60 Million Upfront Payment from UCB for Atg-201 License Deal

Reuters
·
Jul 13

Soochow Securities Starts Antengene at Buy With HK$10.60 Price Target

MT Newswires Live
·
Jul 10

Antengene Executes HKD 1.00 Million Share Buyback, Boosts Treasury Stock to 450,000 Shares

Bulletin Express
·
Jul 09

Antengene Files HKEX Next-day Disclosure Return on Share Repurchase for Treasury Shares

Reuters
·
Jul 09

Antengene Corp Intends to Repurchase up to 67.92 Million Shares

Reuters
·
Jun 25

Antengene Plans HK$50.00 Million On-Market Share Buyback Covering Up to 10% of Issued Shares

Bulletin Express
·
Jun 25

ANTENGENE-B to Initiate On-Market Share Buyback Program

Stock News
·
Jun 25

Antengene Plans up to HK$50 Million On-market Share Buyback

Reuters
·
Jun 25

Antengene Corp - Intends to Repurchase up to 67.92 Mln Shares

THOMSON REUTERS
·
Jun 25

Antengene Corp - Board Resolves to Repurchase Shares up to HK$50 Mln Aggregate Consideration

THOMSON REUTERS
·
Jun 25

Antengene to Spin Off TCE Assets into New Entity for Global Expansion

Deep News
·
Jun 22

BRIEF-Antengene Corp Enters Exclusive License Agreement With K2 Therapeutics For Atg-106

Reuters
·
Jun 22

Antengene-B Inks Exclusive Licensing Deal with K2 Therapeutics for ATG-106 and Grants Option for Undisclosed Bispecific TCE

Stock News
·
Jun 22

Antengene clinches USD 20.00 million global licensing deal with K2 Therapeutics for ATG-106; milestones may add USD 960.50 million and mirrors terms for optional second TCE

Bulletin Express
·
Jun 22

Antengene licenses ATG-106 bispecific T-cell engager to MPM BioImpact’s K2 Therapeutics for USD 20 million upfront

Reuters
·
Jun 22

Antengene Corp - to Receive About $20 Mln Upfront and Near-Term Consideration

THOMSON REUTERS
·
Jun 22

Antengene Corp - Enters Exclusive License Agreement With K2 Therapeutics for Atg-106

THOMSON REUTERS
·
Jun 22